Meeder Asset Management’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.92M | Buy |
10,911
+10,525
| +2,727% | +$3.22M | 0.2% | 101 |
|
|
2026
Q1 | $96.7K | Buy |
386
+195
| +102% | +$48.5K | 0.01% | 367 |
|
|
2025
Q4 | $52.6K | Buy |
191
+174
| +1,024% | +$47.6K | ﹤0.01% | 388 |
|
|
2025
Q3 | $4.46K | Hold |
17
| – | – | ﹤0.01% | 692 |
|
|
2025
Q2 | $3.72K | Sell |
17
-628
| -97% | -$134K | ﹤0.01% | 751 |
|
|
2025
Q1 | $144K | Sell |
645
-7
| -1% | -$1.93K | 0.01% | 280 |
|
|
2024
Q4 | $214K | Sell |
652
-1
| -0.2% | -$315 | 0.01% | 217 |
|
|
2024
Q3 | $196K | Buy |
653
+353
| +118% | +$108K | 0.01% | 223 |
|
|
2024
Q2 | $98.8K | Buy |
300
+278
| +1,264% | +$98.2K | 0.01% | 263 |
|
|
2024
Q1 | $8.71K | Buy |
+22
| New | +$8.14K | ﹤0.01% | 570 |
|
|
2023
Q3 | – | Sell |
-8,938
| Closed | -$3.42M | – | 595 |
|
|
2023
Q2 | $3.42M | Hold |
8,938
| – | – | 0.25% | 90 |
|
|
2023
Q1 | $3.1M | Buy |
8,938
+1,212
| +16% | +$354K | 0.25% | 95 |
|
|
2022
Q4 | $1.82M | Sell |
7,726
-4,938
| -39% | -$1.17M | 0.16% | 141 |
|
|
2022
Q3 | $3.12M | Sell |
12,664
-357
| -3% | -$109K | 0.18% | 102 |
|
|
2022
Q2 | $3.94M | Buy |
13,021
+637
| +5% | +$207K | 0.23% | 88 |
|
|
2022
Q1 | $5.09M | Buy |
12,384
+1,238
| +11% | +$485K | 0.25% | 81 |
|
|
2021
Q4 | $5.23M | Buy |
11,146
+8,150
| +272% | +$3.51M | 0.53% | 40 |
|
|
2021
Q3 | $1.27M | Sell |
2,996
-1,398
| -32% | -$589K | 0.07% | 231 |
|
|
2021
Q2 | $1.58M | Sell |
4,394
-802
| -15% | -$265K | 0.07% | 202 |
|
|
2021
Q1 | $1.46M | Buy |
5,196
+4,925
| +1,817% | +$1.41M | 0.08% | 212 |
|
|
2020
Q4 | $77K | Sell |
271
-4,694
| -95% | -$1.32M | 0.02% | 484 |
|
|
2020
Q3 | $1.36M | Buy |
4,965
+16
| +0.3% | +$4.23K | 0.09% | 190 |
|
|
2020
Q2 | $1.12M | Buy |
4,949
+273
| +6% | +$53.6K | 0.07% | 227 |
|
|
2020
Q1 | $713K | Buy |
4,676
+2,795
| +149% | +$430K | 0.06% | 263 |
|
|
2019
Q4 | $282K | Buy |
1,881
+12
| +0.6% | +$1.75K | 0.02% | 509 |
|
|
2019
Q3 | $265K | Buy |
1,869
+611
| +49% | +$84.1K | 0.02% | 540 |
|
|
2019
Q2 | $157K | Sell |
1,258
-250
| -17% | -$29.5K | 0.01% | 634 |
|
|
2019
Q1 | $167K | Sell |
1,508
-4,368
| -74% | -$454K | 0.01% | 579 |
|
|
2018
Q4 | $576K | Buy |
5,876
+5,056
| +617% | +$549K | 0.05% | 300 |
|
|
2018
Q3 | $101K | Buy |
+820
| New | +$92K | 0.01% | 642 |
|
|
2018
Q2 | – | Sell |
-380
| Closed | -$34K | – | 1695 |
|
|
2018
Q1 | $34K | Buy |
380
+328
| +631% | +$30.7K | ﹤0.01% | 759 |
|
|
2017
Q4 | $5K | Buy |
+52
| New | +$5.1K | ﹤0.01% | 1326 |
|
|
2017
Q3 | – | Sell |
-1,034
| Closed | -$98K | – | 1781 |
|
|
2017
Q2 | $98K | Buy |
+1,034
| New | +$95.1K | 0.01% | 563 |
|
Other funds holding WST
GIM
Meeder Asset Management's WST Position: Q2 2026 in Review
Meeder Asset Management increased its West Pharmaceutical (WST) stake by 2,727% in Q2 2026, buying an estimated $3.22M and bringing the position to 10,911 shares worth $3.92M. The position accounts for 0.2% of the portfolio, ranked #101.
Meeder Asset Management first reported a position in WST in Q2 2017 and has held it in 33 quarters since. The position peaked at $5.23M in Q4 2021. 832 funds tracked by Wall St. Rank hold WST as of Q2 2026.
- Meeder Asset Management held 10,911 shares of West Pharmaceutical worth $3.92M as of Q2 2026.
- Meeder Asset Management bought 10,525 West Pharmaceutical shares in Q2 2026, an estimated $3.22M.
- West Pharmaceutical made up 0.2% of Meeder Asset Management's portfolio in Q2 2026, its #101 holding.
- Meeder Asset Management first reported a position in West Pharmaceutical in Q2 2017 and has held it in 33 quarters since.
- Meeder Asset Management's West Pharmaceutical position peaked at $5.23M in Q4 2021.
- 832 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.
Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.